Navigation Links
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
Date:12/3/2008

ecome pregnant while taking Gleevec tablets and to avoid breast-feeding while taking Gleevec tablets because of the potential for serious adverse reactions in nursing infants. Sexually active female patients taking Gleevec should use adequate contraception. If the patient does become pregnant while taking Gleevec, the patient should be advised of the potential hazard to the fetus.

Severe (NCI Grades 3/4) lab abnormalities -- including neutropenia (3.6%-48%), anemia (1%-42%), thrombocytopenia (<1%-33%) and hepatotoxicity (approx 5%) -- and severe adverse experiences (NCI Grades 3/4), including severe fluid retention (e.g., pleural effusion, pulmonary edema and ascites) and superficial edema (1.3%-11%), hemorrhage (1.8%-19%) and musculoskeletal pain (2%-9%) were reported among patients receiving Gleevec*. Severe fluid retention appears to be dose-related, was more common in the advanced phase studies (where the dosage was 600 mg/day), and is more common in the elderly.

Severe congestive heart failure and left ventricular dysfunction have occasionally been reported. Most of the patients with reported cardiac events have had other co-morbidities and risk factors, including advanced age and previous medical history of cardiac disease. Patients with cardiac disease or risk factors for cardiac failure should be monitored carefully, and any patient with signs or symptoms consistent with cardiac failure should be evaluated and treated.

Dose adjustments may be necessary due to hepatotoxicity, other nonhematologic adverse reactions, or hematologic adverse reactions. Therapy with Gleevec was discontinued for drug-related adverse reactions in 2.4% to 5% of patients. Complete blood counts should be performed weekly for the first month, biweekly for the second month, and periodically thereafter as clinically indicated (for example, every 2-3 months).

A 25% decrease in the recommended dose should
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
4. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
5. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
6. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. New Conflict of Interest Violations Revealed at California Stem Cell Institute
9. St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia
10. Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
11. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... LAKE CITY, Dec. 15 ... has signed a preferred vendor agreement to provide ... Providers, Inc. (PTP), a nationwide network of physical, ... to be working with Preferred Therapy Providers," said ... and marketing at Dynatronics. "Their vast network of ...
(Date:12/15/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, Systemic Lupus ... Market Forecasts to 2015 ,, ... Lupus Erythematosus - Drug Pipeline Analysis ... Summary ,, GlobalData, the ...
(Date:12/15/2009)... Dec. 15 Waters Corporation (NYSE: ... Vision Publisher(TM) (v.7.1 SR4), an electronic laboratory notebook ... (SDMS), a secure electronic repository that stores and ... centralized database and is used to boost efficiency ... with the SAFE-BioPharma digital identity and signature standard. ...
Breaking Medicine Technology:Dynatronics Inks Preferred Vendor Agreement with 1,100 Member Preferred Therapy Providers, Inc. 2Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 2Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 3Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 4Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 5Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 6Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 7Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 8Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 2Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 3Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 4Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 5Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 6Bupa International Website Turns Spotlight on Health 56359 1Bupa International Website Turns Spotlight on Health 56359 2Bupa International Website Turns Spotlight on Health 56359 3The Simple ABCs of Weight Loss and Fitness 56356 1The Simple ABCs of Weight Loss and Fitness 56356 2The Simple ABCs of Weight Loss and Fitness 56356 3Update on velaglucerase alfa 13884 1Update on velaglucerase alfa 13884 2Update on velaglucerase alfa 13884 3
... Compendia Bioscience, Inc.,today announced results of a second ... all major customers and the addition of,several "Top ... The new,customers and existing customer commitment expansions led ... growth forecasted for 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20070213/NYTU093LOGO ...
... Joseph F. Finn, Jr.,CPA, the Assignee for ... design of a clinical trial to investigate whether ... Rifalazil, the,most potent anti-chlamydial agent that has been ... for Chlamydia STD. The insidious aspect,of Chlamydia STD ...
Other Medicine Technology:On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments 2On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments 3ActivBiotics Outlines a Clinical Path Forward to Examine if Rifalazil Is Superior to Azithromycin in the Treatment of Chlamydia STD 2
(Date:12/15/2009)... ,we would have really been in trouble, expert says ... of the pandemic H1N1 swine flu has revealed serious ... health emergencies, a new report says. , The report, ... Robert Wood Johnson Foundation, also finds the dire economy ... "The 2009 H1N1 outbreak is the latest in a ...
(Date:12/15/2009)... tests promised but not delivered ,, WASHINGTON, ... on Congress to ensure that healthcare reform does ... required of insurance companies in 37 states. ,, ... segments of the population and individuals who are ... and men who have a family history of ...
(Date:12/15/2009)... -- 4R Systems, Inc., a leading provider of ... retailers significantly increase profits by optimizing their inventory ... The Vitamin Shoppe has been utilizing the 4R ... DC inventory solutions have helped us drive significant ... the last two years," said Tony Truesdale, President ...
(Date:12/15/2009)... 15 The following are the remarks ... the criminal division, at the Medicare Fraud Strike ... And thank you for the enormous effort everyone ... ,, Together, our Departments have and will ... We,ve made tremendous progress in fighting Medicare fraud ...
(Date:12/15/2009)... Lead to Indictment of 30 Individuals Charged in ... Million in Fraudulent Billing to Medicare ... have been charged in three cities for their ... $61 million in false Medicare claims as part ... Strike Force, Department of Health and Human Services ...
Breaking Medicine News(10 mins):Health News:Serious Gaps Revealed in U.S. Response to Health Emergencies 2Health News:Serious Gaps Revealed in U.S. Response to Health Emergencies 3Health News:Men's Health Network Calls on Congress to Complete President Obama's Promise on Health Care Reform 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 3Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 4Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 2Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 3Health News:Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La. 2Health News:Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La. 3Health News:Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La. 4Health News:Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La. 5
... Technologies (OTC Bulletin Board: PSTX) today announced that ... senior notes with net proceeds of $2.0 million. ... towards funding the continued growth of its primary ... of tracking systems for surgical sponges."As hospitals face ...
... Angeles-based HR Consulting firm, a new white paper reveals how small businesses ... ... (PRWEB) January 30, 2009 -- Due to a grim economic forecast for ... help relieve their recession woes. This is according to a new white ...
... 10 tips for getting through the backlog to help claimants with ... ... 2009 -- The increase in people applying for Social Security disability ... their entitled benefits, according to Allsup , which represents tens ...
... and Future Growth Opportunities in Transplant Diagnostics and Genetic ... 30 Gen-Probe Incorporated (Nasdaq: GPRO ), ... human disease, announced today that it has offered to ... Life Sciences, PLC (AIM: TED), a rapidly growing molecular ...
... Tobacco-Free KidsWASHINGTON, Jan. 29 The U.S. ... by voting to increase federal tobacco taxes, including a ... and expansion of the State Children,s Health Insurance ... future for millions of children both by reducing tobacco ...
... presented today at the American,Academy of Pain Medicine,s ... about pain during the experience of pain, and ... the central,nervous system that mediate pain sensations. ... Previous studies have looked at physiological,responses to ...
Other Medicine News:Health News:CPEhr Releases New White Paper Highlighting Value of Human Resources Outsourcing In A Recession 2Health News:CPEhr Releases New White Paper Highlighting Value of Human Resources Outsourcing In A Recession 3Health News:Applications for Social Security Disability Reach 2.6 Million 2Health News:Applications for Social Security Disability Reach 2.6 Million 3Health News:Applications for Social Security Disability Reach 2.6 Million 4Health News:Applications for Social Security Disability Reach 2.6 Million 5Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 2Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 3Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 4Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 5Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 6Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 7Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 8Health News:U.S. Senate Acts to Protect Kids, Save Lives by Increasing Federal Tobacco Taxes 2Health News:Negative Emotions About Pain Increase Pro-Inflammatory Response 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: